Applied Molecular Transport Inc (AMTI) Stock
AMTI is no longer traded. Applied Molecular Transport Inc was delisted from the Nasdaq in December 2023.
Prices on this page are historical; the last trade was December 26, 2023 at $0.26.
Applied Molecular Transport Inc stock price history
AMTI final trading statistics
- Final close
- $0.26
- Final trading day
- Dec 26, 2023
- Market cap at delisting
- $11.01M
- Shares outstanding
- 41.85M
- Final 52-week range
- $0.13 – $0.84
- Avg. volume (final 3 mo.)
- 370,868
- All-time high (split-adj.)
- $74.14 · Mar 2021
- All-time low (split-adj.)
- $0.14 · Nov 2023
- Return since IPO
- -98.5%
- Beta
- 2.29
- Book value / share
- $0.40
- Price / book
- 0.66
Applied Molecular Transport Inc annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $0.00 | -$125.4M | -$3.26 |
| FY2021 | $0.00 | -$96.4M | -$2.66 |
| FY2020 | $0.00 | -$64.5M | -$2.86 |
| FY2019 | $0.00 | -$28.0M | — |
| FY2018 | $0.00 | -$29.9M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Applied Molecular Transport Inc
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.
Applied Molecular Transport Inc stock FAQ
What happened to Applied Molecular Transport Inc stock?
Applied Molecular Transport Inc stock was delisted from the Nasdaq. Its final close was $0.26 on December 26, 2023.
Is AMTI stock still trading?
No. AMTI was delisted from the Nasdaq in December 2023 and no longer trades on a U.S. exchange.
What was the last price of AMTI stock?
AMTI closed at $0.26 on its final trading day, December 26, 2023, for a market value of about $11.01M.
What were Applied Molecular Transport Inc's revenue and earnings in its last full fiscal year?
Applied Molecular Transport Inc reported revenue of $0.00 and net income of -$125.4M in fiscal 2022, its last full year as a public company.
When did Applied Molecular Transport Inc go public?
Applied Molecular Transport Inc stock began trading on June 5, 2020.